Medical/Pharmaceuticals
Neurophet Showcases 'Brain Imaging AI Solutions' at BIO USA, Accelerates Global Business Development Collaborations
* Introduces key products including an integrated brain imaging analysis solution for Alzheimer's disease treatment decision-making * Expands partnering efforts with global pharmaceutical and biotech companies as well as potential customers, while introducing its ICL services SEOUL, South Kor...
2026-06-16 21:00
5555
2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy
Revolutionizing Treatments for Blood Cancers and Solid Tumors TAIPEI, June 16, 2026 /PRNewswire/ -- On June 16, the Tang Prize in Biopharmaceutical Science announced its 2026 laureates. Three leading scientists in the field of cellular immunotherapy, Drs. Steven A. Rosenberg, Michel Sadelain, an...
2026-06-16 20:30
861
Crescom Launches Global PoC of Pediatric Musculoskeletal AI with Mass General Brigham
Mass General Brigham Department of Radiology Begins Clinical Validation and Utility of Three MediAI Pediatric Solutions BOSTON and SEOUL, South Korea, June 16, 2026 /PRNewswire/ -- Crescom (CEO Jae Joon Lee), a medical AI company specializing in musculoskeletal analysis, has officially launched ...
2026-06-16 20:10
4162
2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy
Revolutionizing Treatments for Blood Cancers and Solid Tumors TAIPEI, June 16, 2026 /PRNewswire/ -- On June 16, the Tang Prize in Biopharmaceutical Science announced its 2026 laureates. The prize, whose laureates from previous cycles have subsequently received Nobel Prize honors, has drawn wide ...
2026-06-16 20:00
4411
DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES
* Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia * 500,000-1 million people are estimated to be living with FSGS in the territories[1] * Dimerix eligible to ...
2026-06-16 19:00
3146
Informa Markets and Thailand's Health Ministry Join Forces To Deliver a Successful Edition of International Healthcare Week 2026 in Bangkok
BANGKOK, June 16, 2026 /PRNewswire/ -- Informa Markets joins forces with Thailand's Department of Health Service Support (DHSS) to unveil International Healthcare Week 2026, a transformative regional healthcare platform that will elevate Thailand's position as a world-leading medical and wellness...
2026-06-16 12:24
3389
DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES
* Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia * 500,000-1 million people are estimated to be living with FSGS in the territories[1] * Dimerix eligible to ...
2026-06-16 10:53
6043
Minghui Pharmaceutical Presents Compelling Phase I/II Results for MHB018A, a Novel Subcutaneous Anti-IGF-1R Antibody for Thyroid Eye Disease, in an Oral Presentation at ENDO 2026, the Endocrine Society's Annual Meeting
* MHB018A demonstrated outstanding clinical activity in both active and chronic thyroid eye disease * At 450 mg Q4W, MHB018A achieved a remarkable 81% proptosis response at Week 12 in active TED and a 76% proptosis response at Week 24 in chronic TED * MHB018A was generally well tolerated amo...
2026-06-16 09:00
6196
Revolutionizing Cancer Treatment: MAaGI Medical's "i" Series Multimodal Tumor Therapy Technique Globally Debuted
SHANGHAI, June 15, 2026 /PRNewswire/ -- In the summer of Suzhou, a distinguished gathering of eminent professionals convened. From June 11 to 14, 2026, the 20th Annual Scientific Meeting of the Asia Pacific Society of Cardiovascular and Interventional Radiology (APSCVIR 2026) was ceremoniously h...
2026-06-15 20:20
4888
Harbour BioMed and BioMap Jointly Initiate MegaStream TechBio: A Leading Global Drug Development Platform Joins Forces with Premier Life Science Foundation Models to Set New Benchmarks for AI-Driven Complex Biologics R&D
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 15, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142.HK), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, and BioMap, a global...
2026-06-15 20:10
5307
Halia Therapeutics Receives FDA Fast Track Designation for Ofirnoflast (HT-6184) in Lower-Risk Myelodysplastic Syndromes
Designation follows Phase 2 data showing durable transfusion independence and multilineage hematological improvement; full results presented at EHA2026 LEHI, Utah, June 15, 2026 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class therapie...
2026-06-15 20:00
3315
Six Regional Organisations Sign MoU to Strengthen Asia's Dengue Response as Cases Rise
Announced at the 9th Asia Dengue Summit in conjunction with ASEAN Dengue Day and the first WHO-recognised World Dengue Day, the MoU establishes a regional framework for knowledge-sharing, advocacy and coordinated dengue action. SINGAPORE, June 15, 2026 /PRNewswire/ -- The Asia Dengue Voice an...
2026-06-15 19:30
4922
Bambusa Therapeutics Presents Positive Preliminary Multiple Ascending Dose Phase 1 Data for BBT002 at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026
- BBT002 is a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-5 - - BBT002 demonstrated rapid, deep, and sustained biomarker effects through at least 8 weeks following multiple doses, consistent with the SAD data, with a ...
2026-06-15 19:00
3050
Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy
HONG KONG, June 15, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926) today announced that the first patient has been enrolled in the Phase Ib/II clinical study (AK138D1-202) evaluating its internally developed next-generation HER3 antibody-drug conjugate (ADC), AK138D1, as either monotherapy or in c...
2026-06-15 14:52
4903
VARON Encourages Oxygen Users to Enjoy Soccer Season with Confidence at Home and On the Go
NEW YORK, June 14, 2026 /PRNewswire/ -- Soccer season brings excitement, community, and unforgettable moments for millions of fans worldwide. Whether gathering with family to watch a match at home, meeting friends at a local sports bar, or traveling to experience the atmosphere of a live game, ox...
2026-06-15 13:40
4687
Kingworld Medicines Group (01110.HK) Signs MOU to Pursue Exclusive Distribution Rights for Two Lingnan Formula Products
Targeting Full-Channel Sales Coverage in Hong Kong, Mainland China and Cross-border E-commerce HONG KONG, June 15, 2026 /PRNewswire/ -- Kingworld Medicines Group Limited ("Kingworld Medicines" or the "Group", Stock Code: 01110.HK) announced that Morning Gold Medicine Company Limited ("Morning Go...
2026-06-15 13:08
5700
Rznomics Presents Clinical Interim Data for RZ-001 in Recurrent Glioblastoma at ASNO 2026
* Dr. Chae-Yong Kim of Seoul National University Bundang Hospital delivers oral presentation on interim data from 10 enrolled patients * A manageable safety profile, with prolonged disease control and tumor recurrence inhibition observed in several patients SEONGNAM and SEOUL, South Korea, Ju...
2026-06-15 12:00
4418
Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape
* The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery platform * Delaware jury finds infringement willful and patent valid, and awards full $20.2 million in da...
2026-06-15 08:01
4745
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
* The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for the combination arm vs 28% for the control arm at week 24. * Post-hoc analysis from the phase 3 SENTRY trial ...
2026-06-14 21:57
4564
Luxel Corporation Appoints KOS, Inc. as Exclusive Distributor in South Korea
FRIDAY HARBOR, Wash., June 13, 2026 /PRNewswire/ -- Luxel Corporation, a global leader in the design and manufacture of ultrathin freestanding polymer and metallized optical bandpass filters, today announced the appointment of KOS, Inc. as its exclusive distribution partner for South Korea, effec...
2026-06-13 06:36
6571
Week's Top Stories
Most Reposted
Visa and Lianlian Advance Trusted B2B Agentic Commerce Through LoopXPay's First Live B2B Agentic Transaction
[Picked up by 318 media titles]
2026-07-24 12:00
Ascentium Welcomes MGI Dobbyn Carafa, Strengthening Advisory Capability in Australia
[Picked up by 297 media titles]
2026-07-20 15:00
A New Chapter Begins: Peach Blossoms Returns to Level 5 with the Debut of its Black Pearl One Diamond Tasting Journey
[Picked up by 295 media titles]
2026-07-23 16:00
Phuket Marriott Resort & Spa, Merlin Beach Elevates Guest Experience with New Dining and Family Facilities
[Picked up by 292 media titles]
2026-07-24 18:32
Courtyard by Marriott Phuket, Patong Beach Wins TripAdvisor Best of the Best Award
[Picked up by 289 media titles]
2026-07-24 16:25
Most Read
Ascentium Welcomes MGI Dobbyn Carafa, Strengthening Advisory Capability in Australia
2026-07-20 15:00
15998
A New Chapter Begins: Peach Blossoms Returns to Level 5 with the Debut of its Black Pearl One Diamond Tasting Journey
2026-07-23 16:00
7062
Omni HR Launches Native MCP Integration, Connecting AI Assistants to Live HR Data
2026-07-20 11:00
7045
